Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLN-481 in Healthy Adult Participants
NCT07903064Phase 1Not yet recruiting
- Sponsor
- Beeline Medicines
- Start
- Oct 2026
- Primary completion
- Nov 2027
01
Overview
Phase 1, randomised, double-blind trial comparing BLN-481 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events and Serious Adverse Events at 24 weeks, Safety Laboratory Tests at 20 weeks and 7 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
BLN-481
Beyond the preview
Go deeper on NCT07903064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903064.